TORONTO, Oct. 17, 2025 /CNW/ - Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio ...
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...
Hosted on MSN
Eli Lilly stock rises after late-stage data shows longer survival with breast cancer drug
・The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the drug with Abemaciclib extended key treatment timelines compared with using it ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results